Netspot imaging12/22/2023 ![]() ![]() With the GalliaPharm® Ge-68/Ga-68 generator and Yttriga, sterile Yttrium-90 chloride solution, Radiopharma GmbH provides two core pharmaceutical products for diagnosis and therapy. The company is specialized in the field of nuclear medicine and molecular imaging, providing radiopharmaceuticals and radiochemicals for diagnosis, treatment and research purposes. Eckert & Ziegler Radiopharma GmbH is also a holder of a Type II Drug Master File (#28741) in the USA.Īccording to CNETS, with approximately 12,000-15,000 1 Canadians living with NETs, this form of cancer has gone from being once rare to one of the fastest-growing classes of cancer worldwide.ġ CNETS - Canadian Neuroendocrine Tumor SocietyĮckert & Ziegler Radiopharma GmbH is a wholly owned subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG and part of Eckert & Ziegler's Medical business segment. It is registered as a medicinal product in 17 European countries and Canada. GalliaPharm® is available with the following activities: 740 MBq, 1110 MBq, 1480 MBq and 1850 MBq (20 mCi, 30 mCi, 40 mCi, 50 mCi). "As the exclusive distribution partner of the GalliaPharm® generator in Canada, we are very pleased to provide state-of-the-art diagnostic services to more Canadian patients suffering from cancer, while also helping healthcare professionals realize the value of new and novel nuclear medicine products," stated Sergio Calvo, President of Jubilant's Radiopharmaceuticals Division. ![]() "Therefore, after the successful approval of GalliaPharm® by Health Canada in 2020, this marks another important milestone for making such diagnostics broadly available to nuclear medicine practices and clinics in Canada together with our partners from Jubilant Radiopharma™." ![]() Harald Hasselmann, Eckert & Ziegler Executive Director and responsible for the Medical segment. "NETSPOT® is the only registered Ga-68 based radiopharmaceutical in Canada," explained Dr. 22, 2021 (GLOBE NEWSWIRE) - On June 30, 2021, Health Canada approved Eckert & Ziegler Radiopharma's GalliaPharm® Ge68/Ga-68 generator for use with Advance Accelerator Systems' NETSpot kit used for the localization of somatostatin receptor positive neuroendocrine tumors (NET) in adult patients using Positron Emission Tomography (PET). ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |